Abivax completes pre-NDA meeting with FDA for ulcerative colitis drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to Abivax completes pre-NDA meeting with FDA for ulcerative colitis drug

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

July 30, 2026 4:05 PM EDT

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026

PARIS, France July 30, 2026 10:05 p.m. CEST Abivax SA (Euronext Paris: FR0012333284 ABVX / Nasdaq: ABVX) (Abivax or the Company), a clinical-stage biotechnology... More